Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma (Q38063500)

28 August 2017

1 reference

9 September 2020

Clinical studies applying cytokine-induced killer cells for the treatment of renal cell carcinoma (English)

1 reference

28 August 2017

1 reference

9 September 2020

1 reference

9 September 2020

adoptive immunotherapy

1 reference

cytokine-induced killer cell

1 August 2020

1 reference

9 September 2020

Clara E Jäkel

1

1 reference

28 August 2017

Stefan Hauser

2

1 reference

28 August 2017

Sebastian Rogenhofer

3

1 reference

28 August 2017

Stefan C Müller

4

1 reference

28 August 2017

P Brossart

5

1 reference

28 August 2017

Ingo G H Schmidt-Wolf

6

1 reference

28 August 2017

language of work or name

1 reference

6 November 2012

8 references

Clinical and Developmental Immunology

28 August 2017

3 April 2019

25 June 2019

19 September 2019

12 October 2019

18 October 2019

1 August 2020

9 September 2020

9 references

28 August 2017

3 April 2019

25 June 2019

19 September 2019

12 October 2019

18 October 2019

29 May 2020

1 August 2020

9 September 2020

2012

1 reference

28 August 2017

473245

1 reference

Creative Commons Attribution 3.0 Unported

28 August 2017

7 references

3 April 2019

25 June 2019

19 September 2019

12 October 2019

18 October 2019

1 August 2020

on focus list of Wikimedia project

9 September 2020

copyright status

copyrighted

0 references

ScienceSource

0 references

cites work

Current treatment considerations in metastatic renal cell carcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Clinical trials on CIK cells: first report of the international registry on CIK cells (IRCC).

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Immunotherapy of metastatic renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

CD4 +CD25 + regulatory T cells decreased the antitumor activity of cytokine-induced killer (CIK) cells of lung cancer patients

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Recent progress in the management of advanced renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Phase I clinical study applying autologous immunological effector cells transfected with the interleukin-2 gene in patients with metastatic renal cancer, colorectal cancer and lymphoma

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICA and MICB

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cells.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

A novel population of expanded human CD3+CD56+ cells derived from T cells with potent in vivo antitumor activity in mice with severe combined immunodeficiency.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 to patients with metastatic cancer

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Use of a SCID mouse/human lymphoma model to evaluate cytokine-induced killer cells with potent antitumor cell activity

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Interleukin-6 inhibits regulatory T cells and improves the proliferation and cytotoxic activity of cytokine-induced killer cells.

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours: a pilot clinical trial

6 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Th1 bias in PBMC induced by multicycles of auto-CIKs infusion in malignant solid tumor patients

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Role of NKG2D signaling in the cytotoxicity of activated and expanded CD8+ T cells

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Telomerase pulsed dendritic cells for immunotherapy for renal cell carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Phase I trial of concurrent twice-weekly recombinant human interleukin-12 plus low-dose IL-2 in patients with melanoma or renal cell carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Phase I trial of twice-weekly intravenous interleukin 12 in patients with metastatic renal cell cancer or malignant melanoma: ability to maintain IFN-gamma induction is associated with clinical response

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Hormonal therapy and chemotherapy of renal-cell carcinoma

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Prospects for adoptive T cell therapy

14 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Interleukin 2 for patients with renal cancer

28 September 2017

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Successful immunotherapy of murine experimental hepatic metastases with lymphokine-activated killer cells and recombinant interleukin 2.

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Randomized study of autologous cytokine-induced killer cell immunotherapy in metastatic renal carcinoma

23 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Cytokine-induced killer cells are terminally differentiated activated CD8 cytotoxic T-EMRA lymphocytes.

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Immunosensitization of resistant human tumor cells to cytotoxicity by tumor infiltrating lymphocytes

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Engineering hematopoietic grafts: purified allogeneic hematopoietic stem cells plus expanded CD8+ NK-T cells in the treatment of lymphoma

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Phase I trial of subcutaneous recombinant human interleukin-12 in patients with advanced renal cell carcinoma

31 August 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=3501961

Functional expression and release of ligands for the activating immunoreceptor NKG2D in leukemia

31 August 2018

1 reference

Crossref

https://api.crossref.org/works/10.1155%2F2012%2F473245

[Efficacy of autologous renal tumor cell lysate-loaded dendritic cell vaccine in combination with cytokine-induced killer cells on advanced renal cell carcinoma--a report of ten cases]

21 January 2018

1 reference

12 December 2020

Immunotherapy with cytokine-induced killer cells in metastatic renal cell carcinoma

1 reference

12 December 2020

CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells

1 reference

12 December 2020

Major histocompatibility complex class I-related chain A and UL16-binding protein expression on tumor cell lines of different histotypes: analysis of tumor susceptibility to NKG2D-dependent natural killer cell cytotoxicity

1 reference

12 December 2020

Adoptive Immunotherapy of Established Pulmonary Metastases with LAK Cells and Recombinant Interleukin-2

1 reference

12 December 2020

A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes

1 reference

12 December 2020

Inhibition of human colon cancer growth by antibody-directed human LAK cells in SCID mice

1 reference

12 December 2020

Propagation of large numbers of T cells with natural killer cell markers

1 reference

12 December 2020

Potential of autologous immunologic effector cells for bone marrow purging in patients with chronic myeloid leukemia

1 reference

12 December 2020

Sensitivity of multidrug-resistant tumor cell lines to immunologic effector cells

1 reference

12 December 2020

Identifiers

DOI

10.1155/2012/473245

1 reference

28 August 2017

1 reference

28 August 2017

PubMed publication ID

23193418

1 reference